Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Protagonist Therapeutics, Inc. (PTGX : NSDQ)
 
 • Company Description   
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Number of Employees: 132

 
 • Price / Volume Information   
Yesterday's Closing Price: $99.19 Daily Weekly Monthly
20 Day Moving Average: 583,192 shares
Shares Outstanding: 64.31 (millions)
Market Capitalization: $6,379.01 (millions)
Beta: 1.89
52 Week High: $107.84
52 Week Low: $45.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.34% -8.06%
12 Week 12.22% 3.74%
Year To Date 13.57% 7.38%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7707 GATEWAY BLVD. SUITE 140
-
NEWARK,CA 94560
USA		 ph: 510-474-0170
fax: -		 info@ptgx-inc.com http://www.protagonist-inc.com
 
 • General Corporate Information   
Officers
Dinesh V. Patel - President; Chief Executive Officer and Director
Harold E. Selick - Chairman
Asif Ali - Executive Vice President; Chief Financial Officer
Bryan Giraudo - Director
Sarah O'Dowd - Director

Peer Information
Protagonist Therapeutics, Inc. (CORR.)
Protagonist Therapeutics, Inc. (RSPI)
Protagonist Therapeutics, Inc. (CGXP)
Protagonist Therapeutics, Inc. (BGEN)
Protagonist Therapeutics, Inc. (GTBP)
Protagonist Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74366E102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/05/26
Share - Related Items
Shares Outstanding: 64.31
Most Recent Split Date: (:1)
Beta: 1.89
Market Capitalization: $6,379.01 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $2.29 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 38.95
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 9.73
Price/Cash Flow: -
Price / Sales: 86.13
EPS Growth
vs. Year Ago Period: 126.32%
vs. Previous Quarter: 107.25%
Sales Growth
vs. Year Ago Period: 99.03%
vs. Previous Quarter: 657.94%
ROE
03/31/26 - -17.76
12/31/25 - -19.89
09/30/25 - 6.86
ROA
03/31/26 - -16.47
12/31/25 - -18.40
09/30/25 - 6.32
Current Ratio
03/31/26 - 17.76
12/31/25 - 12.71
09/30/25 - 13.05
Quick Ratio
03/31/26 - 17.76
12/31/25 - 12.71
09/30/25 - 13.05
Operating Margin
03/31/26 - -154.88
12/31/25 - -282.83
09/30/25 - 21.94
Net Margin
03/31/26 - -154.88
12/31/25 - -282.83
09/30/25 - 21.94
Pre-Tax Margin
03/31/26 - -155.78
12/31/25 - -281.01
09/30/25 - 22.98
Book Value
03/31/26 - 10.19
12/31/25 - 9.83
09/30/25 - 10.32
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©